May 19, 2022
Article
The symptoms of serotonin syndrome often include autonomic dysfunction, neuromuscular excitation, and altered mental status.
Specialty pharmacy is deeply engaged in providing treatment for conditions that are at high risk for mental health challenges.
May 17, 2022
Naxitamab-gqgk (Danyelza) is for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
May 13, 2022
Studies have estimated that 16% of people with dementia experience depression, but this may be as high as 40%, demonstrating a great need for effective treatments.
May 12, 2022
Serotonin syndrome generally occurs within 6 hours of a change in dose or addition of medication.
May 11, 2022
Researchers also noted the importance of patient-reported outcomes due to the fluctuating and unpredictable nature of generalized myasthenia gravis and the subjectivity of symptoms.
April 28, 2022
Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.
April 26, 2022
Fremanezumab is the second FDA-approved preventive migraine treatment that blocks the activity of calcitonin gene-related peptide.
April 25, 2022
Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.
April 22, 2022
New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.
